Reach out if you'd like to discuss how we can work together!
Experience and services in:
- Bioinformatics algorithm development, pipelines, data architecture
- Cancer biology, infectious & autoimmune diseases, population genetics, multi-omics
- Technical strategy & solutions
CNVkit v0.9.10 is out!
https://t.co/Zhl6kmIgdF
New plotting features, better GISTIC support, and many bug fixes and infrastructure improvements. Much thanks to contributors over the past ~2 years.
If you could read the DNA of half a million people, would you do it and why? Would it work? What would you learn?
To answer this and several related questions, let me walk you through the work my @RegeneronDNA colleagues just published in Nature. 1/24
https://t.co/5Xd7HmfnI6
If you're interested in trying @nf_core in the context of reproducible peer review I am looking for a participant for a short survey and a test of robustness on disputed m6a paper. $250 recompense. Please DM me for details.
@rlim_Hsapiens @biocrusoe Not personally, but I understand it's basically an extension of Parquet and will work in the same scenarios, plus a few more.
R has a number of packages that are just datasets, not code. Has this been tried with conda or other package managers in order to make datasets versioned and traceable?
@dpryan79 Thanks. This would be for derived or accruing datasets that downstream pipelines then depend on, e.g. I've validated a pipeline with RefGene from <date>, and want to pin all its dependencies in code. The data itself doesn't even need to be copied, necessarily.
You can now link reviews from the preprint on biorxiv.
Another step towards a journal-free open science utopia with preprint and post publication peer review. :D
https://t.co/SblSX0zBAq
I'm hiring for the Data Core at @KariusInc!
https://t.co/fWk4OC7y3t
We mine biological datasets to power a cfDNA test for infectious diseases. We discover new things every day.
HQ is in the Bay Area; remote is also fine.
The Karius test works for clinical diagnosis of infectious diseases: https://t.co/BXeUbqVggo
What's next? We'll go beyond n-of-1, improve the assay itself and its clinical validity, use the assay to make discoveries, and much more.
Open source software experience and scientific community engagement would be great. We're looking to work with the global community to bring new discoveries into the open. Again, we've seen things in the blood microbiome that no one else has.
TODAY @ 3PM ET: Join @mlipsitch and other experts for The Science of Herd Immunity.
They will explain the science of and misconceptions around herd immunity and discuss new research frontiers in immunology, infectious disease dynamics, and human behavior. https://t.co/TsSvqck2ly
I'm now at @KariusInc !
We have a lifesaving noninvasive test for infectious diseases, and from another perspective, a metagenomic cfDNA assay that works as a powerful new molecular microscope for understanding human physiology.